Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global CIS Insulin Market report, 2014 – 2020

syndicate market research
Posted on: 13 Sep 16

Insulin regulates metabolism by creating the pancreas that allows your body to use glucose from carbohydrates in the food.  Insulin helps to keep your blood sugar level from getting too high or too low. Insulin enables the entry of glucose in the cell and maintains level of blood glucose. In diabetes treatment, patient need insulin injections to allow body to process sugar and avoid complications from hyperglycemia

Browse full report @

Rising ubiquity of diabetes is one of the important factors bolstering the growth of the CIS insulin market. The increasing pervasiveness of obesity disorder is expected to be imperative for this industry. The prominent circumstances that might occur owing to this disorder include type II diabetes, obesity and hypertension. The government supports and rising R&D in insulin product is projected to exhibit lucrative growth in this industry. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period.

The report provides a detailed view of the CIS insulin market based on products, application and region.  Based on products, CIS insulin market is further bifurcated into long acting, short acting, rapid acting, premixed and intermediate acting.   Long acting insulin accounted for a very large chunk of the global CIS insulin market. Rapid acting is another leading project and expected to exhibit strong growth over the forecast period. The CIS insulin market is further classified based on source into analogs and human recombinant. The analog segment holds largest share of the CIS insulin market.  Key applications of insulin include type I and other diabetes and type II diabetes. Type II diabetes dominated CIS insulin market and accounted for significant share of total market.        

Get request Sample @

Regional segmentation includes the current and forecast demand of CIS insulin in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil. The CIS insulin market is dominated by North America followed by Europe. Asia Pacific is expected to witness significant growth over the forecast period.

The report covers detailed competitive scenario including the company overviews, financial revenues of the key participants to develop their positions in the global market. Major market players include Merck & Co. Inc., Novo Nordisk, Eli Lilly and Company, Oramed Pharmaceuticals, Nanjing Xinbai Pharmaceutical Co. Ltd., Sanofi Aventis, Boehringer Ingelheim, Farmak and Biocon. 

Get Illustrative Sample before buying:

This report segments the global CIS insulin market as follows:

CIS Insulin Market: Product Segment Analysis

Long Acting
Short Acting
Rapid Acting
Intermediate Acting

CIS Insulin Market: Source Segment Analysis

Human Recombinant

CIS Insulin Market: Application Segment Analysis

Type I Diabetes
Type II Diabetes

CIS Insulin Market: Regional Segment Analysis

North America


Asia Pacific
Latin America
Middle East & Africa

Contact US

3422 SW 15 Street, Suit #8138,
Deerfield Beach,Florida 33442, 
USATel:  +1-386-310-3803GMT FREE 

Tel:  +49-322 210 92714 
USA/Canada Toll Free No. 1-855-465-4651 FREE



Editor's Details

kara kirkland

Last updated on: 13/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.